- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma
November 23, 2022
Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.
Lung Cancer Awareness Month: New Targeted Therapy Options in Advanced NSCLC
November 23, 2022
Surabhi Pathak, MD, reviews current and upcoming targeted treatments in patients with non–small cell lung cancer for Lung Cancer Awareness Month.
Understanding Recent Developments in Mantle Cell Lymphoma
November 23, 2022
In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.
Intratumoral Injection Shows Antitumor Activity and Safety in Sarcoma
November 23, 2022
Investigators in the IT-01 trial of INT230-6 as monotherapy or combined with ipilimumab showed safety and potential efficacy in patients with sarcoma.
Key Takeaways of the Survival Outcomes From the LEAP-002 Trial for HCC
November 23, 2022
Richard S. Finn, MD, discusses key takeaways of the LEAP-002 trial of frontline pembrolizumab and lenvatinib for hepatocellular carcinoma.
Verstovsek Highlights Future Directions for MPN Treatments
November 23, 2022
In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the current MPN treatment landscape and where the field is shifting.
Efebera Discusses Different Regimens for Transplant-Eligible NDMM
November 23, 2022
During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market
November 22, 2022
After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.
Updated Findings of Ponatinib/Blinatumomab Combo in Ph+ ALL are Encouraging
November 22, 2022
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22, 2022
With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
Roundtable Discussion: Barata and Participants Explore Later-Line Options in Bladder Cancer
November 22, 2022
During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL
November 22, 2022
In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.